donna graham, executive director revenue cycle jennifer ......jennifer davis, director pfs 1. drug...
TRANSCRIPT
Opioids as it relates to Revenue CycleDonna Graham, Executive Director Revenue Cycle
Jennifer Davis, Director PFS
1
Drug Overdoes Rates 1999-2016➢Ohio leads the nation in per capita overdose deaths and has become the posterchild of the crisis in national media
➢Drug overdoses are now the leading cause of death for Americans under 50 years old nationally (Quinones 2017).
2
Causes of Death in Ohio➢Overdose deaths are now the leading cause of death for Ohioans under the age of 55 and the sixth leading cause of death overall.
➢More than two and a half times as many people die from drug overdoses than in car accidents in Ohio
3
Cost of Opioid Abuse & Dependency - Ohio
4
Cost Per Capita of Opioid Abuse
5
6
The MetroHealth’s System Journey to Serve Cuyahoga County Residents
2012
88% of Population within 10 min of MH Outpatient Facility
40% of Population within 15 min of MH
Inpatient Facility
• 1 Inpatient facility
• 1 Emergency Depts.
• 20 Outpatient sites
• 3 Pharmacies
• 875,000 visits
• 180,000 unique patients
Integrated Health Delivery System
2018
97% of Population within
10 min of MH Outpatient
Facility
80% of Population within 15 min of MH Inpatient Facility
• 4 Hospitals
• 742 staffed beds
• 628 employed physicians
• 4 Emergency Depts.
• 27 Ambulatory sites
• 9 Pharmacies
• 1,300,000 visits
• 300,000 unique patients
Total Opioid Encounters MH Patient Origin
8
9
45.1%
38.0%
14.0%
2.9%
79.4%
18.4%
0.0%2.2%
37.6%
32.4%
25.1%
4.9%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
Medicaid FFS / HMO Medicare FFS / HMO Commercial Self Pay
MHS Payor Mix Distribution
Narcan Vivitrol MetroHealth
MetroHealth’s Opioid Initiative
➢As a part of a multi-pronged community plan to fight against
opioid addiction and overdose, our initiative is to optimize the
Epic EHR to enable optimal pain management, promote safe
opioid prescriptive practices, identify high risk providers and
patients, and engage patients and providers in reducing the
impact of the opioid epidemic.
10
Power of Best Practice Advisories
11
➢ Epic Medication & Orders Best Practice Advisory #1
➢ Epic Medication & Orders Best Practice Advisory #2
12
Order Validation Check➢ Epic Order Validation #1
➢ Epic Order Validation #2
13
Order Validation Hard Stops
14
Comprehensive treatment including
psychosocial support
Patient requires detox and relapse prevention support
Monthly, extended-release, injectable
Naltrexone (Vivitrol)
Healthcare Provider administered
Outpatient coaching integration – Allied
Professional
Vivitrol Clinic
Vivitrol Clinic: Unique Opportunities
Lower hospital cost in Population Health model and
value based payment system
HOPD Physician Clinic
Specialty Pharmacy
Training for Family Medicine
residents
Applications of external grants
Clinical research and publications
Innovation Community
Outreach
15
Clinic MAT Team16
Vivitrol Medication Adherence Program
17
Initial
15 Minute Video
E&M Visit
Oral Naltrexone Challenge (unless client is delayed in follow up and outside the window of 28 days)
Every 4 Weeks
Urine Toxicology
Urine beta-HCG
Vivitrol Injection ( up to 12 months)
E&M Visit
Every 6 Months
Liver Function Test
Vivitrol Coverage 2018
18
PAYOR NAMEEXPECTED REIMBURSEMENT
PER UNIT AVG ADMINISTERED UNITSTOTAL EXPECTED REIMBURSEMENT
Medicare FFS $3.26 380 $1,239
Medicare HMOs*Buckeye Medicare
Contract Rates 380
*MyCare (Duals)
Medicaid FFS $3.25 380 $1,235
Medicaid HMOs Contract Rates 380
Commercial Contract Rates 380
* Requires Authorization
Vivitrol Billing and Coding Guide:
https://www.vivitrolhcp.com/content/pdfs/billing-and-coding-guide.pdf
Coverage Implications➢Medical Benefits do not provide coverage
➢ Use Pharmaceutical Benefits
➢ Review Available Grants for Coverage
➢Payor Nuances➢Sublocade (buprenorphine-naloxone)
➢Denials: By Injection
➢Preference: Sublingual (oral) or use Vivitrol
➢Appeals with reason for needing Sublocade by injection were denied by CareSource
19
Reimbursable DRG’s
20
DRG 894
Alcohol / Drug Abuse or
Dependence, Left AMA
DRG 895
Psychoses
DRG 896 Behavioral &
Developmental Disorders
DRG 897
Other Mental Disorder
Diagnoses
Top 5 Reimbursable Diagnosis
21
T50.7X6A: Under dosing of analeptics and opioid receptor antagonists, initial encounter
T50.7X5A: Adverse effect of analeptics and opioid receptor antagonists, initial encounter
T50.7X2A: Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter
T50.7X1A: Poisoning by analeptics and opioid receptor antagonists, accidental (unintentional), initial encounter
T40.696A: Under dosing of other narcotics, initial encounter
22
Mobile Vivitrol Unit
FLIPPING THE PARADIGM
➢ MetroHealth continues to provide a
care delivery model focused on
community engagement, outreach,
and wellness at the earliest
opportunity for connection.
Clinic P/L
23
24
Summary of Project: As a part of a multi-pronged community plan to fight against opioid addiction and overdose, this initiative is to optimize the Epic EHR to enable optimal pain management, promote safe opioid prescriptive practices, identify high risk providers and patients, and engage patients and providers in reducing the impact of the opioid epidemic.
Opioid Initiative
Clinical Benefits
• Safer and more accurate prescribing
• Improve provider education• Increase patient education• Improve patient advocacy• Improve treatment• Reduce overdose rate• Alternative medicine• Improved Clinical Decision
Support through Epic Best Practice Alerts (BPA)
Financial Benefits
• Reduced impact of opioid use disorder (OUD)
• Opportunity to participate in grants and other programs with financial impact
Strategic Benefits
• Supports MetroHealth goal to address the opioid crisis in our area.
• Led by the Office of Opioid Safety and Executive Leadership to improve patient safety and reduce risks.
• Meet Medical Board, Federal and OBoP Regulations
Multi-Disciplinary Resources
• Revenue Cycle• Clinical Operations• Information Technology• Providers• Nurses• Finance
Project Score
✓ Financial Return
✓ Patient Safety
✓ Quality
✓ Strategy
✓ Enterprise
✓ Complexity
✓ Regulatory
Contact Information
25
Phone: 216-778-4175Email: [email protected]
Phone: 216-957-2505Email: [email protected]